Dette er en kun kverrulering for det ligger jo en implisitt prising av selskapenes pipeline i dagens market cap…
Når du kjøper en aksje gjør du jo en direkte eller indirekte vurdering av NPV. Summen av alle aktørerers vurdering utgjør prisingen.
I rest my case.
Snakker om å lage problemer ut av ingenting. Alle forsto hva han mente. I tillegg kan du vel droppe emojis i hver setning. Ingen her som er 14 år.
Det er da ingen grunn til å blande to vel definerte begreper som EV og NPV? Det er ikke samme ting som chartet ditt impliserer? 
Når din beregnede NPV > EV, så er det et godt kjøp, ellers er det ikke et godt kjøp, hvis man ser bort i fra trading da. Det er svært sjeldent NPV = EV.
Det var for tidlig på morgenen til at jeg forstod at han mente EV når han skrev NPV. Ser ikke heeelt problemet med emojis? Er 40 forresten. 
Haha, greit. Kan godta tidlig på morgenen, men ro litt ned på emojis 
Må vel få lov å dele meningene sine, og rette på noe hvis det er feil? 
Hva er forresten galt med et smilefjes eller 3? 
Hi
Today’s read is a 2016 paper:
Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database
This figure below shows mortality rate split between extra-hepatic CCA (applicable to pci biotech) and intra-hepatic CCA in the US. For 2014 for example the mortality rate for extra-hepatic CCA was about 0,6 per 100,000. US population in 2014 was 318.6 million, this gives # of deaths due to extra-hepatic CCA in the same year to be 1912
the mortality rate per 100000 seems to be stable, but remember the actual number of deaths will increase with increasing population
Regner jo med at EGF er fullstendig begivenhetsløs, og at emisjonen blir vedtatt med overveldende flertall, men er det noen som er der og kan bekrefte det?
Kommer vel en melding veldig snart…
Det er merkelig og se ett selskap som med fimaVacc og fimaNac, meget mulig sitter med noekkelteknologien til loesning paa kreftgaaten, ligge og vake under milliarden i verdi.
Sammen med snart ett to, eller tresiffret antall partnere, er dette meget sannsynelig.
En annen ting, hvorfor kjoerer ikke PCIB igang preklinisk for bukspyttkjertel kreft? Det er ingen vits aa vente med det.
Finansiell risiko er nok en stor faktor. Det er jo også begrenset hva organisasjonen til PCIB klarer å håndtere.
Først må de få fram spydspissen fimaCHEM. Deretter kanskje noen partneravtaler som gjør dem mer økonomisk slagkraftig og da er det kanskje mer naturlig å begynne å se på hode&nakke samt andre potensielle muligheter 
Kan vel tenkes at ved gokjenning på GGK at behandlingen vil bli brukt offlabel på bukspytkjertelkreft likevel, uten at jeg har sjekket opp i detalj alle mulighetene for behandling som er på den indikasjonen.
PCI Biotech: Rights issue approved by the extraordinary general meeting
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
PCI Biotech: Rights issue approved by the extraordinary general meeting
Oslo, Norway, 14 September 2018. An extraordinary general meeting (the “EGM”) of the shareholders of PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) was held today, 14 September 2018 at 10:00 CEST. 11,453,332 shares were represented at the meeting, corresponding to approximately 45.8 percent of the share capital.
The EGM approved the Board of Directors’ proposed resolutions as set forth in the notice of the EGM issued on 24 August 2018.
The PCI Biotech share will, for trades subject to the ordinary T+2 settlement in the Norwegian Central Securities Depository (VPS), consequently trade exclusive of the right to receive subscription rights in the rights issue from and including Monday, 17 September 2018. Detailed terms of the rights issue will be included in the prospectus, expected to be published on or about 19 September 2018.
The minutes of the EGM are attached, and are also available on www.pcibiotech.com.
The Company expects that the allocation date, whereby allocations in the rights issue will be made and notified to the subscribers, will be on or about 5 October 2018, payment date for the subscription amounts will be on or about 8 October 2018 and the registration of the share capital increase in the Norwegian Register of Business Enterprises will be completed on or about 9 October 2018.
Contact information:
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757
For more information visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, Oslo, N-0379Important Notice
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company. The Company’s financial advisors are acting exclusively for the Company and no one else, and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, or for advice in relation to the Rights Issue, the contents of this announcement or any of the matters referred to herein.The information in this announcement is for information purposes only and does not purport to be accurate or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.
Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “strategy”, “intends”, “estimate”, “will”, “may”, “continue”, “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. Neither the publication and/or delivery of this announcement shall under any circumstances imply that there has been no change in the affairs of the Company or that the information contained herein is correct as of any date subsequent to the earlier of the date hereof and any earlier specified date with respect to such information.
A prospectus approved by the competent authority in Norway is expected to be published by the Company before the Rights Issue commences (if and when made) and, if and when published, can be obtained on the Company’s website, subject to regulatory restrictions. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the prospectus.
Restrictions
Neither this announcement nor any copy of it may be made or transmitted directly or indirectly into the United States, Australia, Canada, Japan, Hong Kong or South Africa or any other jurisdiction where to do so would be unlawful. The Rights Issue (if made) and the distribution of this announcement and other information in connection with the Rights Issue may be restricted by law in certain jurisdictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. Persons into whose possession this announcement or other information should come are required to inform themselves about and observe any such restrictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions.This announcement does not in itself constitute, and should not be construed as, an offer for sale or subscription of or solicitation or invitation of any offer to subscribe for or purchase any securities of the Company or its affiliates in any jurisdiction. The Rights Issue will (if and when made) not be made in any jurisdiction or in any circumstances in which such offer or solicitation would be unlawful. No steps have been taken or will be taken relating to the Rights Issue in any jurisdiction outside of Norway in which such steps would be required.
The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or any securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable state law. There will be no public offer of the securities in the United States.
This announcement is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). This announcement must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons. Persons distributing this announcement must satisfy themselves that it is lawful to do so.
Further information regarding restrictions applicable for the Rights Issue will be set out in the prospectus prepared for the Rights Issue.
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The Company’s lead fimaCHEM programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVACC applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Attachment
PCI Biotech Holding ASA Minutes EGM 14 Sept 2018
Nyheten er levert av GlobeNewswire.
http://www.netfonds.no/quotes/release.php?id=20180914.GlobeNewswire.GNW1000099219-en
Lav prosentandel som deltok, kan man ta det som ett tegn på at det er større mulighet for overtegning ? Mange som ikke følger med på hva som skjer ?
DOMINOS!
Nei, tror ikke det. Heller flere som regner det som planke kjøring.
Sikkert et dumt spørsmål, men så vidt jeg har fått med meg er det antall aksjer man har ved børsslutt i dag som avgjør hvor mange tegningsretter man får. Er det ikke naturlig å anta at mange vil selge på mandag for å få rå til tilstrekkelig t-retter?
Noen leter etter inngang ennå, spørs om ikke porten blir trangere etter den 19 september… En vakker dag i Q4 byttes porten med en smal dør 
